Remove 2014 Remove Healthcare Remove Healthcare Provider Remove Prospecting
article thumbnail

Liron Fendell

Cadensee

Until back in 2014, I met the team at Schneider Children's Medical Center of Israel. And I was lucky enough the team at Schneider's and Clalit Healthcare , who is the owner of Schneider Hospital. So, this was a prospective, randomized, double blind, placebo-controlled study. So, it was just a really frustrating cycle.

Retail 52
article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

The agreement outlined that Par would keep its generic equivalent off the market for as many as two years, delaying the generic launch till September 30, 2014. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. In the US, obesity care is estimated at to cost $147 billion in healthcare spending annually.

Medical 105
article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. In the US, obesity care is estimated at to cost $147 billion in healthcare spending annually.

Medical 98